The Trump administration is planning to pilot covering weight loss drugs. A longtime healthcare exec moves to a strategic advisory role at General Catalyst.

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

In this week’s edition of InnovationRx, we look at a biotech entrepreneur treating a rare genetic disease, new tech aimed at ...

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

Health and Human Services Secretary Robert F. Kennedy Jr said that President Donald Trump calls him up “three or four times a week” to hound him with the same question. At such a critical moment in US ...

The results follow Novo’s worst weekly decline in its history after the company slashed its full-year guidance.

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

Pfizer CEO says drugmakers ‘are all ready to roll up their sleeves and execute’ as president demands more direct-to-consumer options ...

Eli Lilly's stock is lagging the S&P 500 since April, potentially allowing a catch-up trade if results impress. Medicare may ...

Eli Lilly and Company is gearing up for its second quarter earnings report this Thursday, before the market opens. The pharmaceutical giant has witnessed significant revenue boosts from its ...

In the second part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, ...

The Senate nixed a provision to “delink” drug list prices from compensation for PBMs and other drug middlemen days before its ...